In vitro study demonstrates antibacterial and anti-biofilm activity of Ligilactobacillus salivarius derivatives against Staphylococcus aureus, highlighting potential food safety applications.
Ligilactobacillus salivarius has been identified as a putative probiotic, its functional mechanisms and genomic characteristics remain under investigated. In this study, L. salivarius strain PM-A0006 was comprehensively evaluated through integrated whole-genome sequencing and phenotypic characterization. Whole-genome sequencing of L. salivarius PM-A0006 revealed a circular chromosome of 1,877,957 bp with GC content of 32.96% and no virulence factor-related genes were identified. The antibacterial and anti-biofilm activity of cell-free supernatant (CFS) and extracellular vesicles (EVs) was tested on Staphylococcus aureus (ATCC25923) using measurement of inhibition-zone diameters, minimum inhibitory concentration, crystal violet staining and scanning electron microscopy. The results demonstrated that both the CFS and EVs exhibited robust antibacterial and anti-biofilm activities. Liquid chromatography-mass spectrometry analysis revealed that the CFS and EVs were rich in phenyllactic acid, which may be related to their antibacterial properties. Probiotic-derived CFS and EVs are promising antimicrobial candidates due to their safety profiles and multifaceted health benefits. This study demonstrates that the metabolites of L. salivarius PM-A0006 present a safe and potential alternative strategy for preventing staphylococcal risk in food safety.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: